Combination immunotherapy and chemotherapy with cryoablation for lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of an immunotherapy drug (sintilimab), chemotherapy, and a procedure called cryoablation (freezing the tumor) for people with a type of lung cancer called non-small cell lung cancer that has spread or come back. The goal is to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of lung cancer called non-small cell lung cancer (specifically non-squamous) that has spread locally or to other parts of the body, and cannot be removed with surgery.
- Your main tumor is smaller than 5 cm and is in a location that is not too close to major blood vessels or important structures.
- Your cancer does not have certain gene mutations (EGFR or ALK).
- You have at least one tumor that can be measured (as defined by standard criteria).
- You have not had previous treatment for advanced or metastatic cancer, or if you had chemotherapy after surgery, it must have been more than 6 months ago.
- If you have brain metastases, they must be stable or not causing symptoms, and you must not be on high-dose steroids.
- You are generally active and able to take care of yourself (ECOG performance status 0-1).
- Your organ function is adequate (blood counts, etc.).
- You do not have small cell lung cancer or another active cancer within the last 5 years.
- You have not previously been treated with immunotherapy (like PD-1 or PD-L1 inhibitors).
- You are not pregnant or breastfeeding.
- You do not have an active autoimmune disease requiring treatment, and you do not have severe lung function impairment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination treatment for lung cancer that is blocking the airway. It uses freezing (cryoablation) to shrink the tumor in the airway, along with chemotherapy and an immunotherapy drug (a treatment that helps your immune system fight cancer). The goal is to see if this approach is safe and effective for people who have not had prior treatment.
This trial tests a treatment for early-stage lung cancer (stage I-IIA) that uses extreme cold to freeze and destroy the tumor, called cryoablation. Some patients will also receive an immunotherapy drug called serplulimab, which helps the immune system fight the cancer, to see if adding it improves outcomes.
This trial tests a combination of an immunotherapy drug (toripalimab) and a freezing treatment (cryoablation) for people with advanced non-small cell lung cancer that has started to grow again in only a few spots after initial treatment. It aims to see if this approach can help control the cancer without switching to a completely new therapy.
This trial tests whether giving a type of immunotherapy (sintilimab) along with chemotherapy before and after surgery to remove the main lung tumor can help people with advanced non-small cell lung cancer. The goal is to see if this approach improves outcomes compared to standard treatment.
This trial tests whether combining an immunotherapy drug (adebrelimab or retlirafusp alfa) with another drug (recaticimab) and chemotherapy helps shrink lung cancer before surgery. The goal is to see if this approach improves outcomes for people with resectable non-small cell lung cancer.
This trial tests a combination of an immunotherapy drug (sintilimab) with chemotherapy to shrink advanced lung cancer that cannot be removed with surgery. The goal is to see if the cancer becomes operable after treatment and to improve outcomes.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.